Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN

ESC Heart Failure
Bertram PittDavid A Bushinsky

Abstract

Chronic kidney disease (CKD) in heart failure (HF) increases the risk of hyperkalaemia (HK), limiting angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) use. Patiromer is a sodium-free, non-absorbed potassium binder approved for HK treatment. We retrospectively evaluated patiromer's long-term safety and efficacy in HF patients from AMETHYST-DN. Patients with Type 2 diabetes, CKD, and HK [baseline serum potassium >5.0-5.5 mmol/L (mild) or >5.5-<6.0 mmol/L (moderate)], with or without HF (New York Heart Association Class I and II, by investigator judgement), on ACE-I/ARB, were randomized to patiromer 8.4-33.6 g to start, divided twice daily. Overall, 105/304 (35%) patients had HF (75%, Class II). Mean (standard deviation) ejection fraction (EF) was 44.9% (8.2) (n = 81) in patients with HF; 26 had EF ≤40%. In HF patients, mean serum potassium decreased by Day 3 through Week 52. At Week 4, estimated mean (95% confidence interval) change in serum potassium was -0.64 mmol/L (-0.72, -0.55) in mild and -0.97 mmol/L (-1.14, -0.80) in moderate HK (both P < 0.0001). Most HF patients with mild (>88%) and moderate (≥73%) HK had normokalaemia at each visit from Weeks 12 to 52. Three HF patients were withdra...Continue Reading

References

Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Nov 5, 1997·Journal of General Internal Medicine·M A Perazella, R L Mahnensmith
Apr 2, 2003·The New England Journal of Medicine·Bertram PittUNKNOWN Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
Aug 6, 2004·The New England Journal of Medicine·Biff F Palmer
Jun 24, 2009·Archives of Internal Medicine·Lisa M EinhornJeffrey C Fink
Oct 22, 2009·JAMA : the Journal of the American Medical Association·Nancy M AlbertGregg C Fonarow
Nov 16, 2010·The New England Journal of Medicine·Faiez ZannadUNKNOWN EMPHASIS-HF Study Group
Feb 22, 2012·The American Journal of Cardiology·Nishank JainSubhash Banerjee
Jan 17, 2013·The American Journal of Medicine·Ziv HarelChaim M Bell
Jan 30, 2013·BMJ : British Medical Journal·Harikrishna MakaniFranz H Messerli
Aug 27, 2013·International Journal of Clinical Pharmacy·Marianne A KuijvenhovenMirjam Crul
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Nov 22, 2014·The New England Journal of Medicine·Matthew R WeirUNKNOWN OPAL-HK Investigators
Jul 15, 2015·JAMA : the Journal of the American Medical Association·George L BakrisUNKNOWN AMETHYST-DN Investigators
May 18, 2016·Expert Opinion on Pharmacotherapy·Murray Epstein, Bertram Pitt
Sep 30, 2016·Clinical Journal of the American Society of Nephrology : CJASN·David A BushinskyBertram Pitt

❮ Previous
Next ❯

Citations

Mar 14, 2019·Current Opinion in Nephrology and Hypertension·Silvia J LeonNavdeep Tangri
Oct 11, 2019·Current Opinion in Nephrology and Hypertension·Marie Frimodt-MøllerPeter Rossing
Jan 16, 2020·Revista da Associação Médica Brasileira·Renato Watanabe
Jan 24, 2020·Postgraduate Medicine·Csaba P KovesdyBrian C Sauer
Jun 27, 2020·The Cochrane Database of Systematic Reviews·Patrizia NataleGiovanni Fm Strippoli
Mar 7, 2019·European Heart Journal Supplements : Journal of the European Society of Cardiology·Shilpa VijayakumarGeorge L Bakris
Dec 4, 2019·Wiener klinische Wochenschrift·Thomas WeberUNKNOWN Österreichische Gesellschaft für Kinder- und Jugendheilkunde
Dec 5, 2019·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Maxime CoutrotMatthieu Legrand
Jul 22, 2018·Clinical Drug Investigation·Hannah A Blair
Dec 5, 2019·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Angela Yee-Moon Wang
Jan 8, 2020·European Heart Journal Supplements : Journal of the European Society of Cardiology·Patrick RossignolGiuseppe Rosano
May 8, 2020·Cardiovascular Diabetology·Bo LiangNing Gu
Oct 26, 2018·Acta Clinica Belgica·R VanholderE V Nagler
Jun 27, 2019·Herz·I E EmrichM Böhm
May 10, 2020·Internal and Emergency Medicine·Claudia D'AlessandroAdamasco Cupisti
Oct 30, 2020·ESC Heart Failure·Markus S AnkerStephan von Haehling
Nov 9, 2020·Mayo Clinic Proceedings·Biff F PalmerMatthew R Weir
May 28, 2019·Kidney International·Jonatan Barrera-ChimalFrederic Jaisser
Aug 9, 2021·Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation·Steven FishbaneBruce Spinowitz
Aug 28, 2021·European Heart Journal·Theresa A McDonaghUNKNOWN ESC Scientific Document Group

❮ Previous
Next ❯

Software Mentioned

Patiromer
DN
AMETHYST
SAS

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.